Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality

scientific article published in June 2001

Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1528-1157.2001.44300.X
P698PubMed publication ID11422330
P5875ResearchGate publication ID11918795

P50authorIscia Lopes-CendesQ42419183
P2093author name stringAndermann F
Dubeau F
Andermann E
Benjamin A
Duncan S
Seni MH
Mercho S
P2860cites workPrevention of the First Occurrence of Neural-Tube Defects by Periconceptional Vitamin SupplementationQ29615365
Neural-tube defects and derangement of homocysteine metabolismQ44703867
P433issue6
P304page(s)750-753
P577publication date2001-06-01
P1433published inEpilepsiaQ5382969
P1476titleRepeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality
P478volume42

Reverse relations

cites work (P2860)
Q35095179Anti-epileptic drugs in pregnancy: current safety and other issues
Q36292532Birth defects after prenatal exposure to antiepileptic drugs
Q36511300Birth defects and epilepsy medication
Q35147180Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation
Q36697463Currently available antiepileptic drugs
Q37486720Epilepsy pharmacogenetics
Q37426143Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology
Q31046235Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry.
Q34309022Gene–environment interactions, folate metabolism and the embryonic nervous system
Q34722379Management of epilepsy during pregnancy
Q36370360Mode of action: inhibition of histone deacetylase, altering WNT-dependent gene expression, and regulation of beta-catenin--developmental effects of valproic acid
Q80374303Neuropsychological outcomes in children of mothers with epilepsy
Q44880512Oxcarbazepine in pregnancy: clinical experience in Argentina
Q56449619Perinatal outcomes from the use of antiepileptic drugs during pregnancy: a case-control study
Q37869124Pharmacogenetics of drug-induced birth defects: what is known so far?
Q35236942Pregnancy, epilepsy, and anticonvulsants.
Q34910353Prevalence and Correlates of Neural Tube Defect in South West Iran: Retrospective analysis.
Q36235506Safety of antiepileptic drugs during pregnancy
Q43737555Teratogenesis in repeated pregnancies in antiepileptic drug-treated women
Q37301544Teratogenicity and antiepileptic drugs: potential mechanisms
Q37262946Teratogenicity of antiepileptic medications
Q36082034Teratogenicity of sodium valproate
Q36603158Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?
Q36373816Update on pharmacogenetics in epilepsy: a brief review.
Q36729620Various pharmacogenetic aspects of antiepileptic drug therapy: a review